All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, Sobi, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Lilly and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. The symposium was chaired by Gilles Salles and featured presentations by Susan O’Brien, Farrukh Awan, and Francesc Bosch. View each session from the symposium below:
During the Lymphoma Hub virtual symposium, Susan O’Brien, University of California Irvine, US, discussed the mechanism of action of BTK inhibitors and clinical considerations for their use in CLL, as well as remaining unmet needs across the CLL treatment landscape.
During the Lymphoma Hub virtual symposium, Farrukh Awan, University of Texas Southwestern Medical Center, Dallas, US, discussed the use of BTK inhibitors in patients with CLL, including factors influencing treatment selection and emerging clinical evidence.
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Francesc Bosch led a case-based presentation and panel discussion on optimizing chronic lymphocytic leukemia management in a changing landscape.
This educational activity is independently supported by Eli Lilly and Company. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Susan O'Brien
Gilles Salles
Francesc Bosch
Farrukh Awan